SCHEMBL6799643

SCHEMBL6799643

CCn1c(=O)n(O)c(=O)c2cc(F)c(N3CCC(N)C3)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
KDM1A O60341 3/20 0.38
HRH4 Q9H3N8 3/20 0.38
PIM3 Q86V86 3/20 0.37
DYRK1A Q13627 2/20 0.37
PIM1 P11309 2/20 0.37
GSK3A P49840 2/20 0.37
GSK3B P49841 2/20 0.37
PRKD3 O94806 1/20 0.37
IRAK1 P51617 1/20 0.37
RPS6KA3 P51812 1/20 0.37
CSNK1G3 Q9Y6M4 1/20 0.37
EEF2K O00418 2/20 0.37
LMNA P02545 1/20 0.37
CYP2C9 P11712 1/20 0.37
ATP6V1B2 P21281 1/20 0.37
TBXA2R P21731 1/20 0.37
EDNRA P25101 1/20 0.37
TARBP2 Q15633 1/20 0.37
MAT2A P31153 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801438 0.84 LMNA (0.43) KMT2AEEF2KLMNACYP2C9ATP6V1B2
SCHEMBL7012086 0.82 KMT2A (0.43) KMT2AKDM1AHRH4PIM3DYRK1A
SCHEMBL6800242 0.82 LMNA (0.41) KMT2AHRH4EEF2KLMNACYP2C9
SCHEMBL6800507 0.80 KMT2A (0.51) KMT2AKDM1AHRH4GSK3BLMNA
Hydrochloric Acid SCHEMBL7013252 0.79 KMT2A (0.51) KMT2AKDM1AHRH4GSK3BLMNA
SCHEMBL9824535 0.75 KMT2A (0.45) KMT2AKDM1AHRH4PIM3DYRK1A
SCHEMBL9824429 0.75 KMT2A (0.45) KMT2AKDM1ALMNACYP2C9ATP6V1B2
SCHEMBL4515894 0.74 KMT2A (0.48) KMT2AHRH4PIM3DYRK1APIM1
SCHEMBL4515898 0.74 KMT2A (0.48) KMT2AHRH4PIM3DYRK1APIM1
Esafloxacin SCHEMBL1344407 0.73 LMNA (0.69) KMT2AGSK3BLMNACYP2C9ATP6V1B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US claimed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP claimed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US claimed
US-6825199-B2 7-Substituted quinazolin-2,4-diones useful as antibacterial agents WARNER-LAMBERT COMPANY 2004-11-30 US disclosed
EP-1028950-B1 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS WARNER LAMBERT CO (US) 2003-05-02 EP disclosed
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents DOMAGALA JOHN MICHAEL (US) 2002-08-22 US disclosed
US-6331538-B1 TREATMENT OF BACTERIAL INFECTION WARNER-LAMBERT COMPANY 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115674-A1 Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents NQO2, TOP1, TOP2A KMT2A 3798/4885KDM1A 3206/4885HRH4 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.